2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - New Orleans Theatre B
Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

786 Final results of IELSG49: A phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas

Maria Cristina Pirosa, MD, PhD, Markus Raderer, MD2, Stefano Luminari Sr, MD3, Monica Tani4, Gloria Margiotta Casaluci, MD5, Antonella Anastasia, MD6, Alessandro Noto7, Michele Merli, MD8, Marco Brociner, MD9, Gabriele Sapuppo, MD10, Elisabetta Gastaldi11, Nicoletta Ielmini12, Luisella Bonomini13, Francesco Bertoni, MD14, Davide Rossi I, MD, PhD15, Emanuele Zucca, MD16, Anastasios Stathis, MD17
1 EOC Sede Ospedale Regionale di Bellinzona e Valli Bellinzona, Bellinzona, Ticino, Switzerland, Institute of Oncology Research (IOR), Bellinzona, Ticino, Switzerland
2 Medical University of Vienna, Vienna, Austria
3 AUSL IRCCS di Reggio Emilia, Reggio Emilia, Italy
4 AUSL della Romagna, Ravenna, Italy
5 Università del Piemonte Orientale/AOU Maggiore della Carità di Novara, Novara, Italy
6 ASST Spedali Civili di Brescia, Brescia, Italy
7 Fondazione IRCCS Ca' Granda, Milano, Italy
8 Fondazione IRCCS Ca' Granda, Milano, Italy
9 ASST Sette Laghi, Varese, Italy
10 EOC Sede Ospedale Regionale di Bellinzona e Valli Bellinzona, Bellinzona, Ticino, Switzerland
11 Foundation for the Institute of Oncology Research (IOR), Bellinzona, Ticino, Switzerland
12 Foundation for the Institute of Oncology Research (IOR), Bellinzona, Ticino, Switzerland
13 Foundation for the Institute of Oncology Research (IOR), Bellinzona, Ticino, Switzerland
14 EOC Sede Ospedale Regionale di Bellinzona e Valli Bellinzona, Bellinzona, Ticino, Switzerland, Institute of Oncology Research (IOR), Bellinzona, Ticino, Switzerland, Università della Svizzera Italiana, Lugano, Ticino, Switzerland
15 EOC Sede Ospedale Regionale di Bellinzona e Valli Bellinzona, Bellinzona, Ticino, Switzerland, Institute of Oncology Research (IOR), Bellinzona, Ticino, Switzerland, Università della Svizzera Italiana, Lugano, Ticino, Switzerland
16 EOC Sede Ospedale Regionale di Bellinzona e Valli Bellinzona, Bellinzona, Ticino, Switzerland, Foundation for the Institute of Oncology Research (IOR), Bellinzona, Ticino, Switzerland, Institute of Oncology Research (IOR), Bellinzona, Ticino, Switzerland, Università della Svizzera Italiana, Lugano, Ticino, Switzerland
17 EOC Sede Ospedale Regionale di Bellinzona e Valli Bellinzona, Bellinzona, Ticino, Switzerland, Università della Svizzera Italiana, Lugano, Ticino, Switzerland

Introduction
Patients with symptomatic relapsed or refractory (R/R) marginal zone lymphoma (MZL) are commonly treated with single-agent Bruton tyrosine kinase (BTK) inhibitors. The International Extranodal Lymphoma Study Group (IELSG) designed the IELSG49 trial to evaluate the safety and efficacy of a chemotherapy-free regimen combining the anti-CD19 monoclonal antibody tafasitamab with the BTK inhibitor acalabrutinib. Preliminary results were presented at ICML 2025. Here we report the primary endpoint analysis after all patients completed study treatment, together with time-to-event outcomes. 

Methods
This multicenter, single-arm phase II study included a safety run-in and enrolled patients with R/R MZL requiring systemic treatment. Patients received acalabrutinib 100 mg orally twice daily for up to 24 cycles (2 years) combined with tafasitamab 12 mg/kg administered intravenously on days 1, 8, 15, and 22 of cycles 1-3 and on day 1 of cycles 4-24. Disease assessments were performed at weeks 11-13 and at the end of cycles 6, 12, 18, and 24. Patients with complete response (CR), partial response (PR), or stable disease (SD) with clinical benefit continued treatment until completion of 24 cycles or disease progression. The primary endpoint was the best CR rate.

Results
Twenty-six patients were enrolled, of whom 24 were evaluable for efficacy. The median age was 71 years (range, 57–83), with a female-to-male ratio of 16:10. Histologic subtypes included extranodal MZL (n=11), splenic MZL (n=10) and nodal MZL (n=5). Among the extranodal MZL, primary sites were lung (n=4), stomach (n=3), skin (n=2), and orbit and salivary gland for each one. Most patients had ECOG performance status 0 (n=23). Anemia was reported in 11 patients. Disease stage was I/II/IV in 3/2/21 patients, respectively. The median number of prior systemic therapies was 2 (range, 1–5).
At the data cutoff (June 26, 2026), all patients had completed study treatment, including 9 who had discontinued therapy prematurely.
After a median follow-up of 35.1 months, 9 of 24 efficacy-evaluable patients achieved a CR, yielding a CR rate of 37.5% (95% CI, 18.8–59.4%). The overall response rate (ORR) was 75.0% (18/24; 95% CI, 53.3–90.2%). The estimated 3-year PFS was 65.6% (95% CI, 42.7–81.2%), the 3-year duration of response (DoR) was 60.0% (95% CI, 30.8–80.1%), and the 3-year overall survival (OS) was 85.9% (95% CI, 51.1–96.6%).
Six grade ≥3 adverse events (AEs) occurred in three patients, including neutropenia (n=3), thrombocytopenia (n=2), and grade 3 chronic kidney disease (n=1). Eleven serious adverse events (SAEs) were reported in eight patients, including COVID-19 infection (n=2), neuroendocrine tumor (n=2), and one event each of infection (otitis media), acute myocardial infarction, myelodysplastic syndrome, sepsis, neutropenia, surgical excision of a lymphoma lesion, and respiratory infection; only 3 of them were considered drug-related. Treatment was permanently discontinued in 9 patients due to the following reasons: treatment interruption of more than 3 weeks for AE (n=4), disease progression (n=2), stable disease (n=1), and patient refusal (n=2).

Conclusion
The IELSG49 study met its primary endpoint, supporting the activity of the chemotherapy-free combination of tafasitamab and acalabrutinib in R/R MZL. The regimen was well tolerated, with a favorable safety profile and a low incidence of manageable treatment-related adverse events. The high CR rate observed in our study compares favorably with the CR rate of 13% reported for acalabrutinib monotherapy in a similar patient population. Although cross-trial comparisons should be interpreted with caution, this finding suggests that the addition of tafasitamab may improve the depth of response.

Maria Cristina Pirosa, MD, PhD: No relevant conflicts of interest to declare.